Attributions
Manveen Sethi, PhD
Manveen Sethi is an Instructor of Biochemistry at Boston University School of Medicine. Dr. Sethi received her PhD degree from Macquarie University, Australia under the primary supervision of Dr. Morten Thaysen-Andersen, an internationally recognized researcher in Glycobiology. During her Ph.D. work, she studied colorectal cancer cell lines and patient tissue samples using various mass spectrometry proteomics and glycomics. After her PhD, Dr. Sethi was offered a postdoctoral research fellowship at Boston University (BU), MA, with Prof. Joseph Zaia, an internationally acclaimed leader in mass spectrometry (MS) and glycoscience. Currently, Dr. Sethi works as an Instructor under the mentorship of Prof. Zaia. At BU, Dr. Sethi learned (and further developed) MS-based techniques of proteoglycans (PGs) and glycosaminoglycans (GAGs) and applied these techniques to disease models in neurodegenerative disorders including Schizophrenia (SZ) and Alzheimer’s disease (AD). Dr. Sethi performed extensive work to develop and optimize two analytical workflows: tissue digestion for mass spectrometry based glycomics and proteomics profiling enabling analysis of different biomolecules to better understand the role of the extracellular matrix (ECM) of the brain in neurodegeneration. Using these protocols, Dr. Sethi worked on projects involving brain pathophysiology including SZ, AD, and role of drug abuse and performed in-depth mass spectrometry-based glycomics and proteomics characterizations unravel therapeutic targets that can ease symptoms and decelerate disease progression as well as enhance our knowledge of disease pathology. Dr. Sethi wants to establish an analytical glycobiology research group with a focus on unraveling the molecular mechanisms in disease models such as neurodegenerative disorders. With unique and tangible experience in proteoglycan analysis, a strong track-record in neurodegeneration, proteomics, glycobiology, and mass spectrometry, Dr. Sethi has the foundational expertise to contribute to the knowledge base of AD pathology.